's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for in the second quarter 2026?
achieved a return on average equity (ROE) of 9.54 % in its second quarter 2026, this is above SSRI's average return on equity of 0%.
s equity during the 12 months ending in the second quarter 2026 are valued at $3 billion

ROE has advanced compared to 8.72% in the third quarter 2021, due to net income growth.

Within the industry achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the third quarter 2021 at no. .

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter	(Mar 31 2021) I. Quarter	(Dec 31 2017) IV. Quarter
Y / Y Equity Change	-11.84 %	332.92 %	-	-	-
Y / Y Net Income Change	29.34 %	-	-	-	-
Net Income (TTM) in Millions	362	341	277	199	71
Return On Equity (TTM)	9.54 %	8.72 %	8.76 %	9.16 %	6.02 %
SSRI's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	3,392	3,904	3,941	3,942	3,847
Seq. Equity Change	-13.13 %	-0.92 %	-0.02 %	2.45 %	326.57 %
Seq. Net Income Change	44.03 %	-17.5 %	-38.96 %	78.34 %	-

Back to SSRI Management Effectiveness >> SSRI's 5 Years Annual ROE >> Compare SSRI ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

SSRI Annual Return On Equity	(Dec 31 2020) 2020	(Dec 31 2018) 2018	(Dec 31 2017) 2017
Total Equity in Millions	3,847	943	0	0	0
Y / Y Equity Change	307.77 %	-	-	-	-
Net Income in Millions	157	0	71	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	4.09 %	-0 %	-	-	-

Back to SSRI Management Effectiveness >> SSRI's 5 Years Annual ROE >> Compare SSRI ROE to its Competitors

Annual Roe Comment

In 2020 ROE improved to 4.09 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Industry Roe Trends and Statistics
Sector Return On Equity Statistics
SSRI's' Return on Equity at Yahoo Finance
SSRI's Roe Ratio versus Industry, Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SSRI's Competitors
Subscribers only: Roe for 's Suppliers
Subscribers only: Return On Equity for SSRI's Customers

Companies with similar Return On Equity at Jun 30 2026, within Sector	ROE
Hercules Capital Inc	17.16 %
Main Street Capital Corporation	14.81 %
Msc Income Fund Inc	13.47 %
Trinity Capital Inc	12.49 %
Triplepoint Venture Growth Bdc Corp	11.38 %
Capital Southwest Corporation	11.32 %
Fidus Investment Corporation	10.54 %
Chicago Atlantic Bdc Inc	10.45 %
Gladstone Capital Corp	10.25 %
Stellus Capital Investment Corp	8.05 %
Green Thumb Industries Inc.	7.24 %
Whitehorse Finance inc	6.83 %
Ares Capital Corporation	6.78 %
Bain Capital Specialty Finance Inc	5.79 %
Sixth Street Specialty Lending Inc	5.64 %
Nuveen Churchill Direct Lending Corp	5.40 %
Prospect Capital Corp	4.84 %
Blue Owl Technology Finance Corp	4.80 %
Pennantpark Floating Rate Capital Ltd	4.78 %
Blackstone Secured Lending Fund	4.78 %
Goldman Sachs Bdc Inc	4.17 %
Saratoga Investment Corp	4.00 %
Blue Owl Capital Corp	3.98 %
Morgan Stanley Direct Lending Fund	3.48 %
Carlyle Secured Lending Inc	3.25 %
Oaktree Specialty Lending Corporation	2.97 %
Phenixfin Corporation	2.95 %
Pennantpark Investment Corporation	2.26 %

Date modified: 2026-10-15T05:23:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.